Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIM1 | P11309 | 1/20 | 0.47 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.47 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | GRM5 | P41594 | 3/20 | 0.39 |
| ▸ | BTK | Q06187 | 2/20 | 0.38 |
| ▸ | CDK9 | P50750 | 2/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16107306 | 0.84 | PDK4 (0.40) | ALDH1A1ALOX15TSHRMAPK1CDK9 | |
| SCHEMBL29555104 | 0.82 | PRMT5 (0.49) | PRMT5ALDH1A1ALOX15TSHRGRM5 | |
| SCHEMBL16291515 | 0.82 | PRMT5 (0.49) | PRMT5ALDH1A1ALOX15TSHRGRM5 | |
| SCHEMBL25169744 | 0.80 | PRMT5 (0.44) | PRMT5ALDH1A1ALOX15TSHRGRM5 | |
| SCHEMBL28750120 | 0.79 | MEN1 (0.46) | PRMT5ALDH1A1BTKSMN1; SMN2 | |
| SCHEMBL29197644 | 0.78 | CDK9 (0.39) | PRMT5GRM5BTKCDK9MAPT | |
| SCHEMBL29094612 | 0.76 | PRMT5 (0.40) | PRMT5ALDH1A1ALOX15GRM5BTK | |
| SCHEMBL29094666 | 0.76 | GRM5 (0.40) | PRMT5GRM5BTKCDK9PDK4 | |
| SCHEMBL30273891 | 0.75 | GRM5 (0.37) | PRMT5GRM5BTKCDK9PDK4 | |
| SCHEMBL29094575 | 0.74 | CDK9 (0.38) | PRMT5GRM5BTKCDK9MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140296528-A1 | 4-ARYL-1-(BIARYLMETHYLENE) PIPERIDINE COMPOUNDS | KING ABDULAZIZ CITY FOR SCIENCE AND TECHNOLOGY (SA) | 2014-10-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140296528-A1 | 4-ARYL-1-(BIARYLMETHYLENE) PIPERIDINE COMPOUNDS | HTR2C, HTR3C, HTR1D | PIM1 2355/4885PIM2 1533/4885PRMT5 1696/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.